307 related articles for article (PubMed ID: 11526490)
21. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
23. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
[TBL] [Abstract][Full Text] [Related]
24. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
25. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
[TBL] [Abstract][Full Text] [Related]
26. Biology of gastrointestinal stromal tumors.
Corless CL; Fletcher JA; Heinrich MC
J Clin Oncol; 2004 Sep; 22(18):3813-25. PubMed ID: 15365079
[TBL] [Abstract][Full Text] [Related]
27. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
Bertucci F; Goncalves A; Monges G; Madroszyk A; Guiramand J; Moutardier V; Noguchi T; Dubreuil P; Sobol H
Oncol Rep; 2006 Jul; 16(1):97-101. PubMed ID: 16786129
[TBL] [Abstract][Full Text] [Related]
28. Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor.
Sawaki A; Ohashi K; Yamao K; Inada K; Shimizu Y; Matsuura A; Nakamura T; Suzuki T; Hara K; Okubo K; Ohno R
J Gastroenterol; 2003; 38(7):690-4. PubMed ID: 12898363
[TBL] [Abstract][Full Text] [Related]
29. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin BP; Singer S; Tsao C; Duensing A; Lux ML; Ruiz R; Hibbard MK; Chen CJ; Xiao S; Tuveson DA; Demetri GD; Fletcher CD; Fletcher JA
Cancer Res; 2001 Nov; 61(22):8118-21. PubMed ID: 11719439
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
31. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).
Duensing A; Joseph NE; Medeiros F; Smith F; Hornick JL; Heinrich MC; Corless CL; Demetri GD; Fletcher CD; Fletcher JA
Cancer Res; 2004 Aug; 64(15):5127-31. PubMed ID: 15289315
[TBL] [Abstract][Full Text] [Related]
32. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
Sawaki A; Yamao K
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
[TBL] [Abstract][Full Text] [Related]
34. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
35. Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract.
Hirota S; Isozaki K; Nishida T; Kitamura Y
J Gastroenterol; 2000; 35 Suppl 12():75-9. PubMed ID: 10779223
[TBL] [Abstract][Full Text] [Related]
36. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.
Lux ML; Rubin BP; Biase TL; Chen CJ; Maclure T; Demetri G; Xiao S; Singer S; Fletcher CD; Fletcher JA
Am J Pathol; 2000 Mar; 156(3):791-5. PubMed ID: 10702394
[TBL] [Abstract][Full Text] [Related]
37. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).
DeMatteo RP
Ann Surg Oncol; 2002 Nov; 9(9):831-9. PubMed ID: 12417503
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis.
Nagata K; Kawakami T; Kurata Y; Kimura Y; Suzuki Y; Nagata T; Sakuma Y; Miyagi Y; Hirano H
J Proteomics; 2015 Feb; 115():132-42. PubMed ID: 25554490
[TBL] [Abstract][Full Text] [Related]
39. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.
Isozaki K; Terris B; Belghiti J; Schiffmann S; Hirota S; Vanderwinden JM
Am J Pathol; 2000 Nov; 157(5):1581-5. PubMed ID: 11073817
[TBL] [Abstract][Full Text] [Related]
40. Metastatic gastrointestinal stromal tumor with an exon 11 c-kit mutation responding to the tyrosine kinase inhibitor imatinib.
Cho H; Kobayashi O; Tsuburaya A; Sugiyama Y; Sairenji M; Motohashi H; Yoshida T; Miyagi Y; Imada T
Dig Surg; 2004; 21(1):74-7. PubMed ID: 14967957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
